APRE - Aprea's cancer therapy fails in late-stage study

The small-cap biopharmaceutical company, Aprea Therapeutics (APRE) drops 74.2% in premarket trading as the company announces that its lead therapeutic candidate, eprenetapopt, has failed in a Phase 3 trial for myelodysplastic syndrome.Involving 154 TP53 mutant MDS patients, the trial evaluates the safety and efficacy of eprenetapopt with azacitidine versus azacitidine alone in TP53 mutant myelodysplastic syndromes. Per the top-line results, it has not met the predefined primary endpoint of complete remission, the company said. Compared to the control arm, the CR rate was higher in the experimental arm receiving eprenetapopt with AZA, but without statistical significance. However, the combination appeared well-tolerated with an adverse event profile similar to prior Phase 2 clinical trials.Expressing the disappointment over the results, Dr. Eyal Attar, the Chief Medical Officer of Aprea said, “We will continue to analyze data as it matures and follow patients who are still receiving study treatment.”As the graph shows, the stock has lost 45.3% during the

For further details see:

Aprea’s cancer therapy fails in late-stage study